The risk of certain types of cancer appears to be modulated by LRRK2-PD mutations [3]; moreover, noncoding polymorphisms in the LRRK2 locus are associated with an increased risk of leprosy [4] and inflammatory bowel disorder [5]. Here, LRRK2 is linked to leprosy.